Close Menu

HER2 Biomarkers

News and reporting on HER2 biomarkers.

Abbott, Merck Ink Companion Dx Deal to Personalize Unnamed Cancer Treatment

By Turna Ray
Ventana Medical Systems has been in a deal-making frenzy around companion diagnostics development.

This article has been updated from a previous version to clarify information about ongoing efforts to resolve the discordant results of the two studies.
By Ben Butkus

Continuing to expand the development program for its irreversible inhibitor of EGFR and HER2, afatinib, Boehringer Ingelheim Pharmaceuticals has launched two new Phase II studies — one investigating the drug as a treatment for inflammatory breast cancer and another for metastatic

Without speculating on a specific release date for the draft document, FDA's Elizabeth Mansfield said the companion diagnostics guidance is "definitely moving" through the agency.

NanoString is betting that its test will predict treatment benefit for specific classes of chemotherapies, which will differentiate it from other genomic breast cancer tests on the market.

NICE's recommendation for NHS to pay for AstraZeneca's non-small cell lung cancer drug Iressa in EGFR mutation-positive patients marks the second personalized medicine product to be funded in the UK after Herceptin was approved in 2002 for HER2-overexpressing breast cancer patients.

Pages

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.